Nov. 2 at 3:59 PM
$JAZZ "Heads up alert! Only three days until Upcoming earnings on Wednesday, 11/5/2025 for
$JAZZ
Bearish (2.3)
In recent assessments of Jazz Pharmaceuticals (JAZZ), the company has encountered a challenging landscape, particularly in light of its upcoming earnings report, which is expected to reflect a decline in earnings.
The P/E ratio stands at approximately 18.5, which is above the industry average of 15, indicating that the stock may be overvalued given its current performance metrics.
The EPS growth forecast is muted, with analysts projecting a decrease in earnings per share due to anticipated revenue declines.
Revenue forecasts suggest a contraction in the near term, with estimates being revised downward as the market adjusts to the company's recent challenges.
Comparatively, Jazz's performance has been closely aligned with broader market movements, returning 27.1% over the past six months against a 22.9% gain in the S&P 500.
However, the stock's volatility and reliance on upcoming product approvals raise concerns among investors.
Looking ahead to the upcoming earnings report scheduled for November 5, 2025, analysts are bracing for disappointing results.
Historically, Jazz has struggled to meet earnings expectations, and the current consensus estimates suggest a significant shortfall.
This could result in negative sentiment impacting the stock price further.
The recent appointment of Dr.
Ted W.
Love to the Board may provide some strategic insight, yet the immediate financial outlook remains uncertain.
The anticipated decline in earnings could lead to increased scrutiny from investors and analysts alike.
In terms of sector performance, Jazz Pharmaceuticals operates within the biotech industry, which has shown mixed results recently.
While there has been momentum in certain biotech stocks, Jazz's specific challenges, including patent disputes and reliance on a limited pipeline, have placed it at a disadvantage compared to its peers.
Overall, the sector's performance has been buoyed by innovative therapies and strong market demand; however, Jazz's position remains precarious as it navigates through these headwinds.
- Funds were net buyers of
$JAZZ during the previous reporting quarter.
- Funds with large holdings in
$JAZZ include:
- EcoR1 Capital LLC, MV:
$181MM. Fund Rank: 56%
ecor1cap.com
- GMT Capital Corp, MV:
$82MM. Fund Rank: 70%
www.gmtcapital.com
- GW&K Investment Management LLC, MV:
$50MM. Fund Rank: 76%
- Holocene Advisors LP, MV:
$50MM. Fund Rank: 84%
www.holoceneadvisors.com
- Canada Pension , MV:
$26MM. Fund Rank: 78%
- Last 10 days performance: -1%
- Last 30 days performance: 0%
- Last 90 days performance: 19%
Some of the latest news articles:
- Title: 1 Unprofitable Stock with Promising Prospects and 2 Facing Headwinds
Publication Date: 10/31/2025 4:40:21 AM, Source: yahoo
URL: https://finance.yahoo.com/news/1-unprofitable-stock-promising-prospects-044021788.html?.tsrc=rss
- Title: Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
Publication Date: 10/29/2025 2:00:18 PM, Source: yahoo
URL: https://finance.yahoo.com/news/earnings-preview-jazz-pharmaceuticals-jazz-140018384.html?.tsrc=rss
- Title: Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Publication Date: 10/28/2025 8:05:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/jazz-pharmaceuticals-appoints-ted-w-200500183.html?.tsrc=rss
- Title: Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Publication Date: 10/27/2025 9:31:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/basal-cell-nevus-syndrome-market-213100985.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
